Yusong He, MD, PhD
Novartis, Shanghai, China
Dr. Yusong HE graduated from Tongji University School of Medicine, and got his M.D. and Ph.D. degree on Cardiology in 2008. While at Tongji University, he studied molecular and genetic mechanism of familiar atrial fibrillation and found that mutation and dysfunction of inward rectifier potassium channel Kir2.x leads to atrial fibrillation. He also studied the correlation between Ach receptors and atrial fibrillation.
Dr. Yusong HE Joined the Cardiology department of Ruijin Hospital and Institution of Cardiovascular Research and served in 2008. While at Ruijin hospital, he studied the molecular and cellular mechanism of atherosclerosis and illustrated the correlation between non-coding RNA and atherosclerosis and coronary artery disease. This finding first implicated the novel target and mechanism in lipid accumulation of macrophage. He also studied how MSC stem cell contributes to innate inflammatory response in patients with coronary artery disease. He got research fund from NSFC as a leader.
Dr. Yusong HE joined MSD china and served as Health Science Advisor of Medical department in 2009. While at MSD, He was responsible for the investigator initiated science program in diabetes mellitus, and studied the mechanism of the glucagon like peptide -1 on cardiovascular system and retinas.
Dr. Yusong HE joined Novartis China and served Senior Medical Advisor and Manager of Medical Science Liaison of cardiovascular disease from 2010 to today. While at Novartis, he has taken lead large-scale observational studies using advanced device and electronic data collection system, and randomized clinical trials. He also studied community chronic disease management with large database.